Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.
about
Synthesis and cytotoxicity of a biotinylated CC-1065 analogueThe development of immunoconjugates for targeted cancer therapyRadioimmunotherapy of human tumoursReduced antibody response to streptavidin through site-directed mutagenesisMechanisms of action of therapeutic antibodies for cancerBiochemical and biological characterization of a new oxidized avidin with enhanced tissue binding properties.Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab')2 after resection of liver metastases from colorectal cancer.Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I(131) KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma.Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging.Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants.Pretargeted radioimmunotherapy for hematologic and other malignanciesHave we overestimated the benefit of human(ized) antibodies?Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts.Avidin-biotin system pretargeting radioimmunoimaging and radioimmunotherapy and its application in mouse model of human colon carcinomaCancer radioimmunotherapy.Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma.90Y labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapy.Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas.(124)I-huA33 antibody PET of colorectal cancer.Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery.Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry.Improvement of radioimmunotherapy using pretargeting.Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations.A semiempirical model of tumor pretargeting.Antibody-peptide-MHC fusion conjugates target non-cognate T cells to kill tumour cells.Biodistribution and clearance of small molecule hapten chelates for pretargeted radioimmunotherapy.Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy.Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRIT).Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro.Mutations for decreasing the immunogenicity and maintaining the function of core streptavidin.Characterization of poultry egg-white avidins and their potential as a tool in pretargeting cancer treatment.In vivo demonstration of an active tumor pretargeting approach with peptide nucleic acid bioconjugates as complementary system.Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies.Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma
P2860
Q24800845-7442CAC6-4A9E-4CDF-802C-6408BFC65813Q27021990-A407276B-772D-440B-8B49-005F2785BC75Q28088825-8867C4E4-D317-4A9D-BB9F-8F87CA84A251Q28364576-C515AA9A-D505-45CF-B226-AB12F8A1F062Q28385366-576E838B-F17F-41FE-B5E2-BB073EE24422Q30384834-62491A0A-C3D9-41B8-BB1A-F83A4CC233ACQ33301860-2895B460-71C0-4B22-9574-C715C52FB72FQ33379811-685D0C6C-714F-4CFD-B40B-9AC2BC57B393Q33412585-E5FBBF77-89D7-443E-85F1-6FBED2BAA4BBQ33661948-D12D7420-45C7-4C3E-8A66-3CD3E6F4D256Q34029619-59F1114E-D72E-416D-B851-D39D01043F9CQ34113941-FD640E8F-92CE-4032-A458-0AAC09451F02Q34142714-1A3A282C-1B6F-4E05-B6CC-D8BA4B9DC62DQ34762427-BA2C7041-6D4F-4512-AF21-9832BA488CFAQ35059542-797B4DD4-9091-40B1-81EA-2FA9E515E2B5Q35070045-D8ED7086-D761-41EE-AF00-BCF61EE3E1A9Q35589582-430ED333-4A55-47EA-BE28-1E16C2F6FB3EQ35629379-565B0438-A4E3-4D10-985F-6B6EA5D63AE6Q35849837-D2E32399-1CC3-4EE1-ADE6-163B39DEB33CQ36088144-EF51FD43-9CC9-4028-834C-85C0DCE7EC34Q36395999-0741362A-ED22-4203-857A-FC6EBD423DD2Q36690711-7D1F372D-639C-4F31-8011-DDA294657422Q36941931-F34F9CA6-DBAC-452A-9DF5-52704E521875Q36979699-7728D25C-22C9-494B-90C4-94C4469C26AAQ37201878-FB826F4B-8B9E-4D89-A66E-0DB6CA2717A1Q37288717-38E0465A-6F5F-4E4F-B6BB-46F2E1ACA7BFQ37407181-F8E03F2E-DB50-4D7E-8DCB-BD730123FE14Q37656465-419EA1A5-7B85-448E-A70E-22AA52E248AEQ37720857-D665AFC7-6A65-423C-94C1-2FDAC2D8BDE5Q38294018-535ECD8B-6729-4F80-B4CF-231834F30030Q39931512-B3413D80-0F6E-431F-93BF-2923C6D7189AQ41583623-F7F17F72-C21B-4EB7-8E64-2C02C1E86745Q43002836-AB034EC3-0294-4519-B475-5B55468AD8D9Q55093431-96983EB1-B3FA-45A4-BFEB-4DDD04202593Q55709954-2F300F89-FF73-4DCA-BBF2-63FD392668E0Q59133661-AF8FF6ED-8C60-4E1E-92BA-636519F447F9
P2860
Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Phase II trial of yttrium-90-D ...... with metastatic colon cancer.
@ast
Phase II trial of yttrium-90-D ...... with metastatic colon cancer.
@en
Phase II trial of yttrium-90-D ...... with metastatic colon cancer.
@nl
type
label
Phase II trial of yttrium-90-D ...... with metastatic colon cancer.
@ast
Phase II trial of yttrium-90-D ...... with metastatic colon cancer.
@en
Phase II trial of yttrium-90-D ...... with metastatic colon cancer.
@nl
prefLabel
Phase II trial of yttrium-90-D ...... with metastatic colon cancer.
@ast
Phase II trial of yttrium-90-D ...... with metastatic colon cancer.
@en
Phase II trial of yttrium-90-D ...... with metastatic colon cancer.
@nl
P2093
P1476
Phase II trial of yttrium-90-D ...... with metastatic colon cancer.
@en
P2093
Axworthy D
Gaffigan S
P304
P407
P577
2000-02-01T00:00:00Z